ColoSense is the first noninvasive colorectal cancer screening test to offer a view of disease activity through RNA biomarkers, according to a May 6 news release from Geneoscopy.
The company is working with payers, professional societies, and advocacy partners to support a commercial launch later this year or early in 2025, according to the release.
